Ocular Therapeutix
OCUL • NASDAQ
Ocular Therapeutix is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Pravin U. Dugel, with a market cap of $1.6B.
CEOPravin U. Dugel
Next Earnings
Upcoming earnings announcement for Ocular Therapeutix
Date
Monday, May 4, 2026 (in 3 weeks)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.32
Revenue Estimate
$12.7M
Earnings History
Past 12 earnings reports for Ocular Therapeutix
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 5, 2026 | Q4 2025 | -$0.29Est: -$0.33 | +12.1% | $13.3MEst: $15.7M | -15.7% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$0.38Est: -$0.36 | -5.6% | $14.5MEst: $14.1M | +3.2% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.39Est: -$0.35 | -11.4% | $13.5MEst: $13.3M | +1.3% | 10-Q |
| May 5, 2025 | Q1 2025 | -$0.38Est: -$0.28 | -35.7% | $10.7MEst: $17.0M | -36.9% | 10-Q |
| Mar 3, 2025 | Q4 2024 | -$0.29Est: -$0.22 | -31.8% | $17.1MEst: $16.9M | +1.1% | 10-K |
| Nov 14, 2024 | Q3 2024 | -$0.22Est: -$0.21 | -4.8% | $15.4MEst: $17.1M | -10.0% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.26Est: -$0.22 | -18.2% | $16.4MEst: $15.8M | +3.9% | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.28Est: -$0.19 | -47.4% | $14.8MEst: $15.4M | -4.1% | 10-Q |
| Mar 11, 2024 | Q4 2023 | -$0.35Est: -$0.30 | -16.7% | $14.8MEst: $15.7M | -5.8% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.25Est: -$0.29 | +13.8% | $15.1MEst: $15.3M | -1.1% | — |
| Aug 7, 2023 | Q2 2023 | -$0.26Est: -$0.29 | +10.3% | $15.2MEst: $14.6M | +3.7% | 10-Q |
| May 8, 2023 | Q1 2023 | -$0.39Est: -$0.26 | -50.0% | $13.4MEst: $14.1M | -5.1% | — |